BrainScope® has unveiled a major technological leap in neurological diagnostics with the launch of its next-generation deep learning platform, designed to advance brain health assessment across conditions such as concussion, stroke, and early Alzheimer’s detection. Building on its legacy as the developer of the first FDA-cleared AI/machine learning EEG device, BrainScope’s new Large Neural Model brings the power of large language model (LLM) breakthroughs to EEG interpretation. This eliminates the need for traditional qEEG specialists, offering real-time, automated insights that enhance both clinical speed and diagnostic precision.

The platform’s integration into BrainScope’s proprietary system enables clinicians and researchers to extract deeper, more personalized neurological insights. It supports a wide range of clinical applications—from improving triage and diagnosis in emergency settings to enabling precision-driven recruitment and monitoring in clinical trials. With the ability to detect subtle changes in brain activity, the platform opens new pathways for early detection and intervention, particularly in neurodegenerative diseases, where timely treatment can significantly impact outcomes.

To support this expansion, BrainScope has strengthened its leadership team with strategic board appointments. Ralph Terkowitz has been named Chairman of the Board, bringing extensive experience in scaling technology ventures and brain health advocacy. He is joined by seasoned MedTech executive Mike Genau and healthcare investment expert Brian Shea. Their combined expertise is set to guide BrainScope’s next stage of commercial growth and clinical impact. With its enhanced deep learning capabilities and experienced leadership, BrainScope is poised to transform the brain health diagnostics landscape through scalable, AI-powered innovation.

MedTech Spectrum's Summary

Breakthrough in EEG Analysis: BrainScope’s next-gen deep learning platform leverages large neural models to automate EEG interpretation, eliminating the need for specialized analysis and enabling faster, more accurate brain health assessments across conditions like stroke, concussion, and early Alzheimer’s.

Broader Clinical and Research Impact: The platform enhances clinical care and research by supporting early diagnosis, precision treatment, and improved patient outcomes—particularly in time-sensitive and underserved neurological areas.

Strategic Growth and Leadership: With new board appointments including Ralph Terkowitz as Chairman, BrainScope is well-positioned to scale its commercial footprint and drive innovation in AI-enabled brain diagnostics.